Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Intraduodenal administration of intact pea protein effectively reduces food intake in both lean and obese male subjects.

  • 2011-09-13
  • PloS one 6(9)
    • Maartje C P Geraedts
    • Freddy J Troost
    • Marjet J M Munsters
    • Jos H C H Stegen
    • Rogier J de Ridder
    • Jose M Conchillo
    • Joanna W Kruimel
    • Ad A M Masclee
    • Wim H M Saris

Study Design

Type
Randomized Controlled Trial (RCT)
Population
Ten lean (BMI:23.0±0.7 kg/m²) and ten obese (BMI:33.4±1.4 kg/m²) healthy male subjects
Methods
Randomly received either pea protein solutions (250 mg/kg bodyweight in 0.4 ml/kg bodyweight of water) or placebo (0.4 ml/kg bodyweight of water), either orally or intraduodenally via a naso-duodenal tube
Duration
2 h

Background

Human duodenal mucosa secretes increased levels of satiety signals upon exposure to intact protein. However, after oral protein ingestion, gastric digestion leaves little intact proteins to enter the duodenum. This study investigated whether bypassing the stomach, through intraduodenal administration, affects hormone release and food-intake to a larger extent than orally administered protein in both lean and obese subjects.

Methods

Ten lean (BMI:23.0±0.7 kg/m²) and ten obese (BMI:33.4±1.4 kg/m²) healthy male subjects were included. All subjects randomly received either pea protein solutions (250 mg/kg bodyweight in 0.4 ml/kg bodyweight of water) or placebo (0.4 ml/kg bodyweight of water), either orally or intraduodenally via a naso-duodenal tube. Appetite-profile, plasma GLP-1, CCK, and PYY concentrations were determined over a 2 h period. After 2 h, subjects received an ad-libitum meal and food-intake was recorded.

Results

CCK levels were increased at 10(p<0.02) and 20(p<0.01) minutes after intraduodenal protein administration (IPA), in obese subjects, compared to lean subjects, but also compared to oral protein administration (OPA)(p<0.04). GLP-1 levels increased after IPA in obese subjects after 90(p<0.02) to 120(p<0.01) minutes, compared to OPA. Food-intake was reduced after IPA both in lean and obese subjects (-168.9±40 kcal (p<0.01) and -298.2±44 kcal (p<0.01), respectively), compared to placebo. Also, in obese subjects, food-intake was decreased after IPA (-132.6±42 kcal; p<0.01), compared to OPA.

Conclusions

Prevention of gastric proteolysis through bypassing the stomach effectively reduces food intake, and seems to affect obese subjects to a greater extent than lean subjects. Enteric coating of intact protein supplements may provide an effective dietary strategy in the prevention/treatment of obesity.

Research Insights

  • Pea Protein→Increased Cholecystokinin Level

    CCK levels were increased at 10(p<0.02) and 20(p<0.01) minutes after intraduodenal protein administration (IPA), in obese subjects, compared to lean subjects, but also compared to oral protein administration (OPA)(p<0.04).

    Effect
    Beneficial
    Effect size
    Small
    Dose
    250 mg/kg bodyweight in 0.4 ml/kg bodyweight of water
  • Pea Protein→Increased Intestinal GLP-1 Levels

    GLP-1 levels increased after IPA in obese subjects after 90(p<0.02) to 120(p<0.01) minutes, compared to OPA.

    Effect
    Beneficial
    Effect size
    Small
    Dose
    250 mg/kg bodyweight in 0.4 ml/kg bodyweight of water
  • Pea Protein→Reduced Food Intake

    Also, in obese subjects, food-intake was decreased after IPA (-132.6±42 kcal; p<0.01), compared to OPA.

    Effect
    Beneficial
    Effect size
    Moderate
    Dose
    250 mg/kg bodyweight in 0.4 ml/kg bodyweight of water
Back to top